Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Oestrogen-related tumour phenotype: positron emission tomography characterisation with ¹⁸F-FDG and ¹⁸F-FES.

The British journal of radiology - 1 Jul 2012

Tsujikawa T, Yoshida Y, Maeda H, Tsuchida T, Mori T, Kiyono Y, Kimura H, Okazawa H

Abstract excerpt

This article outlines the role of 16α-[(18)F]fluoro-17β-oestradiol ((18)F-FES) positron emission tomography (PET) combined with 2-[(18)F]fluoro-2-deoxy-D-glucose ((18)F-FDG) in patients with oestrogen-related tumours for evaluating tumour phenotype. (18)F-FES-PET combined with (18)F-FDG is helpful in characterising the distinct phenotypic features of oestrogen-related tumours; that is, inter- and intrapatient...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Contrast Media
Share to Endometrial Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Estrogens

Share to Fluorodeoxyglucose F18

Share to Image Enhancement

Share to Neoplasms, Hormone-Dependent

Share to Positron-Emission Tomography

Share to Sensitivity and Specificity

Source

Open in PubMed Open full text

Identifiers

PMID: 22337690
DOI: 10.1259/bjr/26645378
PMCID: PMC3474065

Genes

FES

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Oestrogen-related tumour phenotype: positron emission tomography characterisation with ¹⁸F-FDG and ¹⁸F-FES.PMID 22337690Read ↗

Fluoroestradiol (FES) and Fluorodeoxyglucose (FDG) PET imaging in patients with ER+, HER2-positive or HER2-negative metastatic breast cancerSemantic proximity Read ↗

The use of positron-emission tomography in the diagnosis of tumour phenotype.Semantic proximity Read ↗

18[F]FDG-PET/CT is a useful molecular marker in evaluating tumour aggressiveness: a revised understanding of an in-vivo FDG-PET imaging that alludes the alteration of cancer biology.Semantic proximity Read ↗

PET/CT imaging: The incremental value of assessing the glucose metabolic phenotype and the structure of cancers in a single examination.Semantic proximity Read ↗

18F-16α-17β-Fluoroestradiol Binding Specificity in Estrogen Receptor-Positive Breast Cancer.Semantic proximity Read ↗

Longitudinal Molecular Imaging of Progesterone Receptor Reveals Early Differential Response to Endocrine Therapy in Breast Cancer with an Activating ESR1 Mutation.Semantic proximity Read ↗

Development of novel imaging biomarkers using positron emission tomography for characterization of malignant phenotype and response evaluationSemantic proximity Read ↗

The FAP-FDG Integration Score (FFIS): Development and prognostic validation of a dual-tracer PET phenotype for solid tumors.Semantic proximity Read ↗

The role of 2-[18F]FDG PET/CT in Erdheim-Chester disease.Semantic proximity Read ↗

Utility of positron emission tomography in sarcomasSemantic proximity Read ↗

PET-MR imaging of hypoxia and vascularity in breast cancerSemantic proximity Read ↗

PET/MR in invasive ductal breast cancer: correlation between imaging markers and histological phenotype.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.